Heidelberg, Germany
Heidelberg, Germany

Time filter

Source Type

Browse 187 tables and figures, 11 company profiles spread across 114 pages at http://www.reportsnreports.com/reports/804430-global-mandelic-acid-market-research-report-2017.html . Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Mandelic Acid in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Mandelic Acid in each application. This report studies Mandelic Acid in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Keyuan Biopharm, Runder Pharmda, Zhongke Hua Ang, Hanhong, Xinhetai Science & Technology, Smart Chemicals, BIOTEC, Chunwangda, TNJ, FUXING and R.L.CHEMICAL. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=804430 . The United States Mandelic Acid Industry, 2012-2022 Market Research Report'' is a professional and in-depth study on the current state of the United States Mandelic Acid industry with a focus on the United States market. The report provides key statistics on the market status of the Mandelic Acid manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the United States total market of Mandelic Acid industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of Mandelic Acid industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Mandelic Acid Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 United States Mandelic Acid industry covering all important parameters. The Global and Chinese Mandelic acid Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Mandelic acid industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Mandelic acid market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin. This report studies Load Mandelic Acid in Europe market, focuses on price, sales, revenue of each type in Europe. This report also focuses on the sales (consumption), production, import and export of Load Mandelic Acid in global market, forecast to 2022, from 2017. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Load Mandelic Acid, revenue and market share, for key manufacturers. The Load Mandelic Acid industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers. Connect With Us On:


Browse 187 tables and figures, 11 company profiles spread across 114 pages at http://www.reportsnreports.com/reports/804430-global-mandelic-acid-market-research-report-2017.html . Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Mandelic Acid in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Mandelic Acid in each application. This report studies Mandelic Acid in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Keyuan Biopharm, Runder Pharmda, Zhongke Hua Ang, Hanhong, Xinhetai Science & Technology, Smart Chemicals, BIOTEC, Chunwangda, TNJ, FUXING and R.L.CHEMICAL. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=804430 . The United States Mandelic Acid Industry, 2012-2022 Market Research Report'' is a professional and in-depth study on the current state of the United States Mandelic Acid industry with a focus on the United States market. The report provides key statistics on the market status of the Mandelic Acid manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the United States total market of Mandelic Acid industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of Mandelic Acid industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Mandelic Acid Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 United States Mandelic Acid industry covering all important parameters. The Global and Chinese Mandelic acid Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Mandelic acid industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Mandelic acid market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin. This report studies Load Mandelic Acid in Europe market, focuses on price, sales, revenue of each type in Europe. This report also focuses on the sales (consumption), production, import and export of Load Mandelic Acid in global market, forecast to 2022, from 2017. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Load Mandelic Acid, revenue and market share, for key manufacturers. The Load Mandelic Acid industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers. Connect With Us On:


News Article | May 10, 2017
Site: globenewswire.com

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2”) (NYSE MKT:HCHC), a diversified holding company that focuses on acquiring, operating and growing businesses that it considers to be under or fairly valued, today announced its consolidated results for the first quarter 2017, which ended on March 31, 2017. “The first quarter marked a solid start to the year and a continuation of the many successes we achieved in 2016,” said Philip Falcone, HC2’s Chairman, President and Chief Executive Officer.  “We are very pleased with our first quarter results, which further support our confidence in HC2’s long-term model.  During the quarter, our portfolio performed well, with many subsidiaries achieving significant milestones and accomplishments.  In particular, Global Marine experienced strong operating results with solid performance from their core maintenance and power businesses, in addition to very robust performance from their joint venture with Huawei Marine.  MediBeacon, a company within our Pansend Life Sciences platform, also announced a significant milestone with the successful completion of a key clinical study of its groundbreaking kidney function monitor.” Mr. Falcone continued, “Our momentum has continued into the second quarter, as BeneVir Biopharm, another Pansend Life Sciences company focused on developing oncolytic immunotherapies for the treatment of cancer, recently announced it was granted a key patent that further strengthens its product development program.  In addition, we remained focused on adjusting our capital structure, having again further reduced the cumulative outstanding amount of our Preferred Equity subsequent to the end of the first quarter.  Going forward, we remain focused on reducing our overall cost of capital and continuing to drive the performance of the portfolio, while at the same time seeking opportunities to invest to create long-term value for shareholders.” Mr. Falcone concluded, “As we announced today, we will be transferring our common stock listing from the NYSE MKT to the New York Stock Exchange effective May 16, 2017, under our current ticker symbol 'HCHC'.  The transfer to one of the world’s most prestigious stock exchanges will mark a major milestone for the company and align HC2 with some of the best companies and most influential brands in the world.  We believe listing on the NYSE will enhance trading liquidity of our common stock and contribute to increasing shareholder value.” HC2 Holdings, Inc. will host a live conference call to discuss its first quarter 2017 financial results and operations today, Wednesday, May 10, 2017, at 5:00 p.m. ET. Dial-in instructions for the conference call and the replay are as follows: Alternatively, a live webcast of the conference call can be accessed by interested parties through the Investor Relations section of the HC2 Website, www.HC2.com. *Available approximately two hours after the end of the conference call through June 10, 2017. HC2 Holdings, Inc. is a publicly traded (NYSE MKT:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders.  HC2 has a diverse array of operating subsidiaries across seven reportable segments, including Construction (formerly Manufacturing), Marine Services, Energy (formerly Utilities), Telecommunications, Life Sciences, Insurance and Other.  HC2's largest operating subsidiaries include DBM Global Inc., a family of companies providing fully integrated structural and steel construction services, and Global Marine Systems Limited, a leading provider of engineering and underwater services on submarine cables. Founded in 1994, HC2 is headquartered in New York, New York.  Learn more about HC2 and its portfolio companies at www.hc2.com. For information on HC2 Holdings, Inc., please contact Andrew G. Backman - Managing Director - Investor Relations & Public Relations - abackman@hc2.com - 212-339-5836 In this release, HC2 refers to certain financial measures that are not presented in accordance with U.S. generally accepted accounting principles (“GAAP”), including Core Operating Subsidiary Adjusted EBITDA, Total Adjusted EBITDA (excluding the Insurance segment) and Adjusted EBITDA for its operating segments.  Management believes that Adjusted EBITDA measures provide investors with meaningful information for gaining an understanding of the Company’s results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, because interest, taxes, depreciation, amortization and the other items for which adjustments are made as noted in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. In addition, management uses Adjusted EBITDA measures in evaluating certain of the Company’s segments performance because they eliminate the effects of considerable amounts of non-cash depreciation and amortization and items not within the control of the Company’s operations managers. While management believes that these non-GAAP measurements are useful as supplemental information, such adjusted results are not intended to replace our GAAP financial results and should be read together with HC2’s results reported under GAAP. Management defines Adjusted EBITDA as net income (loss) adjusted to exclude the impact of depreciation and amortization; amortization of equity method fair value adjustments at acquisition; (gain) loss on sale or disposal of assets; lease termination costs; asset impairment expense; loss on early extinguishment or restructuring of debt; interest expense; gain (loss) on contingent consideration; other income (expense), net; foreign currency transaction gain (loss) included in cost of revenue; income tax (benefit) expense; gain (loss) from discontinued operations; non-controlling interest; bonus to be settled in equity; share-based compensation expense and acquisition related and other non-recurring items. A reconciliation of Adjusted EBITDA to Net Income (Loss) is included in the financial tables at the end of this release. Management recognizes that using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other GAAP financial measures, as these non-GAAP measures exclude certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and do not purport to be alternatives to net income (loss) or other GAAP financial measures as a measure of our operating performance. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements. Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. The forward-looking statements in this press release include without limitation statements regarding our expectation regarding building shareholder value.  Such statements are based on the beliefs and assumptions of HC2's management and the management of HC2's subsidiaries and portfolio companies. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent reports on Forms 10-K, 10-Q and 8-K. Such important factors include, without limitation, issues related to the restatement of our financial statements; the fact that we have historically identified material weaknesses in our internal control over financial reporting, and any inability to remediate future material weaknesses; capital market conditions; the ability of HC2's subsidiaries and portfolio companies to generate sufficient net income and cash flows to make upstream cash distributions; volatility in the trading price of HC2 common stock; the ability of HC2 and its subsidiaries and portfolio companies to identify any suitable future acquisition opportunities; our ability to realize efficiencies, cost savings, income and margin improvements, growth, economies of scale and other anticipated benefits of strategic transactions; difficulties related to the integration of financial reporting of acquired or target businesses; difficulties completing pending and future acquisitions and dispositions; effects of litigation, indemnification claims, and other contingent liabilities; changes in regulations and tax laws; and risks that may affect the performance of the operating subsidiaries and portfolio companies of HC2. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to HC2 or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


— There is a prevailing situation of food allergies among the human consuming food; the Food Allergen testing techniques had great opportunity in the market. Growing labelling-compliance in food industry and strict food regulations in the market are the factors boasting the market growth. Immunoassay Based /ELISA segment in the Food Allergen Testing technology market is estimated to dominate the market due to its low costs and accurate & quick results. Moreover, Processed Food segment is expected to attain largest market share, attributing to the increasing number of Food allergy cases related to Processed Food. The North American market is expected to dominate the market owing to the increasing cases of Food Allergy in the food in that particular region. Some of the key players of the Food Allergen Testing market include Alletess Medical Laboratory, ALS Limited, Asurequality Ltd., Charm Sciences, Inc. , Crystal Chem, Inc., Danaher Corporation, Eurofins Central Analytical Laboratories-Eurofins Us , Intertek Group PLC , Merieux Nutrisciences Corporation , Microbac Laboratories, Inc., Neogen Corporation, Omega Diagnostics Group PLC, Perkin Elmer, Inc. , R-Biopharm Ag, Romer Labs Division Holding Gmbh, SGS S.A., Symbio Laboratories and TUV SUD SPB Pte. Ltd. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of APAC • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit: http://www.strategymrc.com For more information, please visit http://www.strategymrc.com/


— Global Enzymatic Debridement Market report covers product scope, market overview, opportunities, risk, and driving force. It analyzes the top manufacturers of Enzymatic Debridement, with sales, revenue, and price in 2016 and 2017. It also display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017. Companies profiled in this research report are Smith & Nephew, Stratus Pharma, WeiBang Biopharm, MediWound and Virchow. Access this report at https://www.themarketreports.com/report/global-enzymatic-debridement-market-by-manufacturers-countries-type-and-application-forecast-to-2022 To provide the historical development this report includes global market by regions, with sales, revenue and market share of Enzymatic Debridement, for each region, from 2012 to 2017 and market analysis by type and application, with sales market share and growth rate by type, application, from 2012 to 2017. This report also analyze the key regions, with sales, revenue and market share by key countries in North America, Europe, Asia-Pacific, South America, and Middle East and Africa. Later, this report provides Enzymatic Debridement Market forecast, by regions, type and application, with sales and revenue, from 2017 to 2022. In addition to above this report includes Enzymatic Debridement sales channel, distributors, traders, dealers, and sum up with research findings and conclusion. Purchase this premium report at: https://www.themarketreports.com/report/buy-now/520914 Market Analysis by Regions • North America (USA, Canada and Mexico) • Europe (Germany, France, UK, Russia and Italy) • Asia-Pacific (China, Japan, Korea, India and Southeast Asia) • South America (Brazil, Argentina, Columbia etc.) • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Inquire about this report at: https://www.themarketreports.com/report/ask-your-query/520914 For more information, please visit https://www.themarketreports.com/report/global-enzymatic-debridement-market-by-manufacturers-countries-type-and-application-forecast-to-2022


News Article | April 26, 2017
Site: www.prweb.com

Allergen Control Group Inc. (ACG) is proud to announce a unique collaboration opportunity with Université Laval’s Institute of Nutrition and Functional Foods (INAF) at the Faculty of Agriculture and Food Science, who have initiated the development of a new platform on Food Risk Analysis and Regulatory Excellence (FRAREP). The platform will build on the expertise available at the Institute and Faculty, to support primary knowledge generation and translation in various areas of food risk analysis. The platform aims to gather available information and generate the missing components, to support food regulatory policy proposals which will be substantiated by a risk analysis approach addressing a gap or an emerging food safety and nutrition issue. The goal of the platform is to translate scientific information underpinning food standards and risk management into “a more usable” form for food regulators and industry alike. The intent is to increase the availability and access of ready-to-use food risk analysis information, which is needed by the food community in addressing regulatory challenges. It also aims to become a focal point for a multi-lingual science-driven source of information for food risk communication, adapted to various audiences. Paul Valder, CEO of the Toronto based Allergen Control Group Inc., states that “as leaders in developing and driving voluntary compliance programs for industry, our interest lies in the area of food allergen and gluten management, which has been selected as the first topic for the application of this platform”. The development of food allergen occurrence data, supported by relevant analytical methods and validated by risk assessment methodologies, and the development of adapted risk management approaches are amongst the areas of focus, with the priority on allergens and gluten sources. Under the leadership of Dr. Samuel Godefroy, a former senior food regulator in Canada with extensive international experience, the platform will host its first Center of Expertise in Food Allergen Research (FoARCE), supported by a partnership with food diagnostics global leader r-Biopharm. r-Biopharm is investing an initial $250,000 USD to support applied research efforts aimed at developing, validating and disseminating allergen and gluten detection methodologies to target research initiatives in food allergen and gluten management. Dr. Godefroy is a Full Professor of Food Risk Analysis at the Department of Food Sciences of Université Laval and a researcher of the Institute. “As a collaborative partner, ACG, owners of the risk based Gluten-Free Certification Program, will support the newly established r-Biopharm Canada/ INAF partnership both domestically and internationally to leverage support and maximize the impact of their research outputs, as we help target a leadership role for food allergen and gluten management,” states Valder. For more information about Allergen Control Group and the Platform, please contact: Jessica Burke, Manager, Compliance & Technical Services Allergen Control Group Inc., owners of the Gluten-Free Certification Program (GFCP) jessica.burke(at)glutenfreecert(dot)com


News Article | October 31, 2016
Site: www.marketwired.com

INDIANAPOLIS, IN--(Marketwired - October 31, 2016) - Apexian Pharmaceutical, Inc., a clinical stage biotechnology company focused on developing novel compounds to treat cancer, today announced the hiring of Richard Messmann, M.D. as Chief Medical Officer (CMO) of the company. "We are extremely pleased to have Rich become our CMO at Apexian Pharmaceuticals," said Steve Carchedi, CEO for the company. "Rich is a proven clinical scientist with an outstanding track record in developing oncology products in both large pharma and the biotech firms. Importantly, in his previous positions, Rich has successfully guided many oncology medicines through their clinical development with the goal of benefiting cancer patients." Apexian recently announced acceptance by the U.S. Food and Drug Administration of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330, a small molecule in development to treat cancer. The Phase 1 study will provide important information on the safety of APX3330 in patients with advanced solid tumors and lay the groundwork for subsequent studies. "I am very excited to join the Apexian team as its Chief Medical Officer," said Dr. Messmann. "This is a critically important time for the company in that we are moving into cancer clinical trials with a novel drug backed by an exemplary scientific team led by Dr. Mark R. Kelley at Indiana University School of Medicine. In addition to APX3330, the company has an impressive pipeline of new compounds that we hope will benefit cancer patients in need of safe and effective therapies." Prior to joining Apexian, Rich was CMO of ProNAi Therapeutics and founder of A.B. Biopharm Consulting Group. Rich has over 25 years of experience in cancer drug development including positions at Eli Lilly & Co., Endocyte, Inc., Great Lakes Cancer Institute at Michigan State University and the National Cancer Institute in Bethesda, MD, where he completed a fellowship in medical oncology before becoming a director at the NCI Developmental Therapeutics Program. Apexian Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel compounds to treat cancer targeting the multiple functions of the APE1 protein. The lead drug candidate, APX3330, initially targets late stage cancer refractory to existing treatments and is expected to begin clinical studies in 2016. To learn more about Apexian, please visit the Company's website at www.Apexianpharma.com


— Age Related Macular Degeneration - Companies Involved in Therapeutics Development are 3SBio Inc, AC Immune SA, Achillion Pharmaceuticals Inc, Aciont Inc, Acucela Inc, AdAlta Ltd, Adverum Biotechnologies Inc, Aerie Pharmaceuticals Inc, Aerpio Therapeutics Inc, Alimera Sciences Inc, Alkeus Pharmaceuticals Inc, Allergan Plc, Allinky Biopharma, Alteogen Inc, Amakem NV, Amarna Therapeutics BV, Ampio Pharmaceuticals Inc, Amyndas Pharmaceuticals LLC, ANP Technologies Inc, Apellis Pharmaceuticals Inc, Apexigen Inc, Applied Genetic Technologies Corp, Astellas Pharma Inc, Benitec Biopharma Ltd, Biokine Therapeutics Ltd, BioMAS Ltd, Biomics Biotechnologies Co Ltd, Biophytis SAS, BLR Bio LLC, Boehringer Ingelheim GmbH, Caladrius Biosciences Inc, Catalyst Biosciences Inc, Cell Cure Neurosciences Ltd, Cell Medica Ltd, Charlesson LLC, Chong Kun Dang Pharmaceutical Corp, Cipla Ltd, Clanotech AB, Clearside BioMedical Inc, Coherus BioSciences Inc, Colby Pharmaceutical Company, Crinetics Pharmaceuticals Inc, Critical Pharmaceuticals Ltd, Daiichi Sankyo Company Ltd, Diffusion Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Eleven Biotherapeutics Inc., Elsalys Biotech SAS, Exonate Ltd, F. Hoffmann-La Roche Ltd, FirstString Research Inc, Foamix Pharmaceuticals Ltd, Formycon AG, Gene Techno Science Co Ltd, Genentech Inc, GenSight Biologics SA, GlaxoSmithKline Plc, Graybug Vision Inc, Grupo Ferrer Internacional SA, HanAll Biopharma Co Ltd, Huabo Biopharm Co Ltd, iCo Therapeutics Inc., Icon Bioscience Inc, Iconic Therapeutics Inc, Inception Sciences Inc, Innovent Biologics Inc, Intellect Neurosciences Inc, International Stem Cell Corp, Ionis Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, Johnson & Johnson, Kala Pharmaceuticals Inc, Kodiak Sciences Inc, Lead Discovery Center GmbH, LeadArtis SL, M's Science Corp, Mabion SA, MacuCLEAR Inc, MeiraGTx Ltd, Mitotech SA, Mitsubishi Tanabe Pharma Corp, Mor Research Application Ltd, Navigen Pharmaceuticals Inc, Navya Biologicals Pvt Ltd, Neovacs SA, Neumedicines Inc, Neuroptis Biotech, Novartis AG, NovelMed Therapeutics Inc, Ocular Therapeutix Inc, Ohr Pharmaceutical Inc, Omeros Corp, Ophthotech Corp, Oxford BioMedica Plc, PanOptica Inc, Pfenex Inc, Pfizer Inc, Precision Ocular Ltd, Promedior Inc, pSivida Corp, QLT Inc, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, Retrotope Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, SanBio Inc, Santen Pharmaceutical Co Ltd, SciFluor Life Sciences LLC, Stealth BioTherapeutics Inc, Sucampo Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, TRACON Pharmaceuticals Inc, TWi Pharmaceuticals Inc, Tyrogenex Inc, Wellstat Ophthalmics Corp and Xbrane Biopharma AB. Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs. The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 33, 11, 109 and 31 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively. Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786897 Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology). • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/


News Article | December 2, 2015
Site: www.nature.com

No statistical methods were used to predetermine sample size. The Ptet-lacY region of the pZE12 Ptet-lacY plasmid43 was amplified with upstream and downstream primers including the digestion sites XhoI and BamHI, respectively, using the primers Ptet-F and lacY-R (see primers below). The resulting DNA fragment was used to replace the corresponding region of Ptet-gfp in the plasmid pZA31-gfp44, yielding the plasmid pZA31 Ptet-lacY. This plasmid was transformed into the titratable PtsG strain NQ1243 to yield NQ1312. The same procedure was employed to generate the lacYA177V mutant (that is, C531T), but fusion PCR was used to introduce a point mutation Val177 into the lacY sequence33. For this, two overlapping parts of the Ptet-lacY region were PCR amplified with the primers ptet-F, lacYfusion-R and lacYfusion-F, lacY-R (see primers below), in which the point substitution C531T leading to the Val177 mutation from ref. 3 was included in the primers lacYfusion-F and lacYfusion-R. These two overlapping DNA fragments were fused together by PCR using primers ptet-F and lacY-R. The resulting Ptet-lacY fragment that carries the desired mutation was inserted into pZA31, yielding pZA31-lacYA177V. The resulting plasmids were transformed into the titratable PtsG strain NQ1243 to yield NQ1313. The ΔflhD deletion allele in strain JW1881-1 (E. coli Genetic Stock Center, Yale University), in which a kanamycin-resistance gene is substituted for the flhD gene, was transferred to the titratable PtsG strain NQ1243 after deletion of kanamycin resistance by phage P1 vir-mediated transduction. Similarly, the ΔfliA allele from strain JW1907 (KEIO collection45), in which a kanamycin-resistance gene is substituted for the fliA gene, was transferred to the titratable PtsG strain NQ1243 after deletion of kanamycin resistance by phage P1 vir-mediated transduction. The following primers for producing the new genetic constructs were used. ptet-F, 5′-ACACTCGAGTCCCTATCAGTGATAGAGATTG-3′, was used for forward amplification of the Ptet sequence and included an XhoI digestion site for construction of pZE1 Ptetstab-lacZ, pZA31-lacY, pZA31-lacYA177V. lacY-R, 5′-TGTGGATCCTTAAGCGACTTCATTCACCTG-3′, was used for reverse amplification of lacY, lacYA177V and included a BamHI digestion site for construction of pZA31-lacY, pZA31-lacYA177V. lacYfusion-F, 5′-CTCTGGCTGTGTACTCATCCTCGCCGTTTTACTCTTTTTCGCCAAAACGG-3′, was used for forward amplification of a fragment of lacY together with the reverse primer lacY-R. This DNA fragment was later used for fusion PCR to construct pZA31-lacYA177V. lacYfusion-R, 5′-CCGTTTTGGCGAAAAAGAGTAAAACGGCGAGGATGAGTACACAGCCAGAG-3′, was used for reverse amplification of a fragment of Ptet-lacY together with the forward primer ptet-F. This DNA fragment later was used for fusion PCR to construct pZA31-lacYA177V. Our growth media were based on the MOPS-buffered minimal medium used previously46 with slight modifications. The base medium contains 40 mM MOPS and 4 mM tricine (adjusted to pH 7.4 with KOH), 0.1 M NaCl, 10 mM NH Cl, 1.32 mM KH PO , 0.523 mM MgCl , 0.276 mM Na SO , 0.1 mM FeSO and the trace micronutrients described previously47. For 15N-labelled media, 15NH Cl was used in place of 14NH Cl. The concentrations of the carbon sources and various supplements used are indicated in the relevant tables. Batch culture growth has been described in detail previously27. To measure CO production from the bacterial growth, cells were grown in a Multifors bioreactor (Infors HT). Medium (400 ml) was used in a 750-ml vessel, which has an inlet for compressed air and out outlet for the exhaust gas. The vessel is otherwise closed except during brief period of sample collection. Samples of the cell culture (for reading A , assaying lactose and acetate, etc) can be taken by using a syringe connected to the vessel. The air flow rate to the inlet was controlled by a mass flow controller (Cole-Parmer, 32907-67) and maintained at 400 ml min−1. The outlet was connected to a BlueInOne Cell sensor unit (BlueSens) for measuring CO concentration. The stir rate in the growth vessel was set as 800 r.p.m. and temperature was maintained at 37 °C. Samples (100 μl) were taken for at least eight different times during exponential growth (typically at A between 0.1 and 0.6) and immediately frozen. Before the assay, samples were thawed in water and immediately centrifuged at maximum speed (13,200g) for 2.5 min. Supernatant (7 μl) was used to measure glucose concentrations using the Glucose Assay Kit (GAHK-20, Sigma-Aldrich). The slope of the plot of glucose concentrations versus A for all replicates (multiplied with the measured growth rate) was used to determine the glucose uptake rate. To assay lactose, ~10 μl of the collected supernatant was first digested by β-galactosidase (Sigma-Aldrich) in Z-buffer at 37 °C for 20 min. The released glucose was then assayed enzymatically by the kit commercially available (Glucose Assay Kit, GAHK20; Sigma-Aldrich). As a control, the sample was treated in the same way without β-galactosidase. Little glucose was detected in the control. Samples (200 μl) were taken for at least three different times during exponential growth (typically at A between 0.1 and 0.6) and immediately frozen. Before the assay, samples were thawed in water and immediately centrifuged at maximum speed (13,200g) for 2.5 min. Supernatant (100 μl) were used to measure acetate concentrations using the Acetate Assay kit (10148261035, R-Biopharm). The slope of the plot of acetate concentrations versus A for all replicates (multiplied with the measured growth rate) was used to determine the acetate excretion rate. The assay was performed following a similar protocol as detailed in a previous study21. Protein mass spectrometry samples were collected from the four bioreactor cultures, a water bath culture of equation (353) grown on glucose minimal medium, and two 15N-labelled water bath cultures of NCM3722 on lactose minimal medium and NQ381 with 200 μM 3-methylbenzyl alcohol. For each of the cultures, 1.8 ml of cell culture at A  = 0.4–0.5 during the exponential phase was collected by centrifugation. The cell pellet was re-suspended in 0.2 ml water and fast frozen on dry ice. Sample preparation and mass spectrometry methods have been described previously28. The raw mass spectrometry data files generated by the AB SCIEX TripleTOF 5600 system were converted to Mascot generic format (mgf) files, which were submitted to the Mascot database searching engine (Matrix Sciences) against the E. coli SwissProt database to identify proteins. The following parameters were used in the Mascot searches: maximum of two missed trypsin cleavage, fixed carbamidomethyl modification, variable oxidation modification, peptide tolerance ±0.1 daltons (Da), MS/MS tolerance ±0.1 Da, and 1+, 2+ and 3+ peptide charge. All peptides with scores less than the identity threshold (P = 0.05) were discarded. The raw mass spectrometry data files were converted to the .mzML and .mgf formats using conversion tools provided by AB Sciex. The .mgf files were used to identify sequencing events against the Mascot database. Finally, results of the Mascot search were submitted with .mzML files to our in-house quantification software48. In brief, intensity is collected for each peptide over a box in retention time and m/z space that encloses the envelope for the light and heavy peaks. The data are collapsed in the retention time dimension and the light and heavy peaks are fit to a multinomial distribution (a function of the chemical formula of each peptide) using a least squares Fourier transform convolution routine49, which yields the relative intensity of the light and heavy species. The ratio of the non-labelled to labelled peaks was obtained for each peptide in each sample. The relative protein quantification data for each protein in each sample mixture was then obtained as a ratio by taking the median of the ratios of its peptides. No ratio (that is, no data) was obtained if there was only one peptide for the protein. The uncertainty for each ratio was defined as the two quartiles associated with the median. To filter out data with poor quality, the ratio was removed for the protein in that sample if at least one of its quartiles lay outside of 50% range of its median. Furthermore, ratios were removed for a protein in all the sample mixtures in a growth limitation if at least one of the ratios has one of its quartiles lying outside of the 100% range of the median. The spectral counting data used for absolute quantitation were extracted from the Mascot search results. For our 15N and 14N mixture samples, only the 14N spectra were counted. The absolute abundance of a protein was calculated by dividing the total number of 14N spectra of all peptides for that protein by the total number of 14N spectra in the sample. For the condition of the LacZ overexpression strain (NQ1389) grown on glucose medium with zero chlorotetracycline level (see source data file of Fig. 2), 15N sample was prepared, that is, NQ1389 grown on glucose minimal medium with 15NH Cl. The sample was mixed with a known amount of purified LacZ protein (Roche Diagnostics, 10745731001), the purity of which was verified both on a SDS–PAGE gel (where a single band was observed) and by checking the spectral counts of 14N peptides in the sample (where ~99% of the 14N peptides are LacZ peptides). With the highly accurate relative protein abundance between the purified 14N LacZ and the 15N LacZ in the sample, the proteome fraction of LacZ in the sample was determined to be 3.3% ± 0.3%. The average Miller Unit (MU) for the same condition was ~20,550 (see source data file of Fig. 2), leading to a converting factor of 1.6% of proteome fraction for 10,000 MU. Biological replicates show the following typical uncertainties in measured quantities: growth rate, ~5%; acetate excretion rates, ~15%; CO evolution rate, ~5%. The parameters and their associated standard errors for linear relations were obtained by carrying out linear regression. Following our approach, multiple measurements over wide ranges of conditions from robust data sets revealing underlying relations between variables. The uncertainties are reported in Extended Data Tables 2 and 3, and throughout the text.

Loading Biopharm GmbH collaborators
Loading Biopharm GmbH collaborators